7. Navigating Liver-Directed Therapy • Dr. Michael Soulen • Penn Medicine • 2026 NCF Conference
In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Michael Soulen, Director of Interventional Oncology at the University of Pennsylvania Abramson Cancer Center, presents *“Navigating Liver-Directed Therapy.”* Dr. Soulen explains why liver metastases are common and clinically important in neuroendocrine tumors, and how biopsy, tumor grade, Ki-67, serial imaging, and genetic sequencing can help guide treatment planning. He also reviews key liver-directed therapy options, including transarterial embolization, chemoembolization, radioembolization, ablation, and radiation-based approaches. This presentation discusses when liver-directed therapy may be considered, including liver-dominant disease, progression on somatostatin analogs, symptom control, bulky liver metastases, and treatment sequencing. Dr. Soulen also covers symptom relief, tumor shrinkage, and post-embolization syndrome. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net. For more information about this conference, visit https://www.ncf.net/events/2026confer... This video is for educational purposes only and is not a substitute for professional medical advice. Please consult your medical team with questions about your individual care or treatment.
In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Michael Soulen, Director of Interventional Oncology at the University of Pennsylvania Abramson Cancer Center, presents *“Navigating Liver-Directed Therapy.”* Dr. Soulen explains why liver metastases are common and clinically important in neuroendocrine tumors, and how biopsy, tumor grade, Ki-67, serial imaging, and genetic sequencing can help guide treatment planning. He also reviews key liver-directed therapy options, including transarterial embolization, chemoembolization, radioembolization, ablation, and radiation-based approaches. This presentation discusses when liver-directed therapy may be considered, including liver-dominant disease, progression on somatostatin analogs, symptom control, bulky liver metastases, and treatment sequencing. Dr. Soulen also covers symptom relief, tumor shrinkage, and post-embolization syndrome. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net. For more information about this conference, visit https://www.ncf.net/events/2026confer... This video is for educational purposes only and is not a substitute for professional medical advice. Please consult your medical team with questions about your individual care or treatment.